COVID-19 vaccine

Part of a series on the
COVID-19 pandemic
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023 January February March April May
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. In January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by March 2020, the global pharmaceutical industry announced a major commitment to address COVID‑19. In 2020, the first COVID‑19 vaccines were developed and made available to the public through emergency authorizations and conditional approvals. Initially, most COVID‑19 vaccines were two-dose vaccines, with the sole exception being the single-dose Janssen COVID-19 vaccine. However, immunity from the vaccines has been found to wane over time, requiring people to get booster doses of the vaccine to maintain protection against COVID‑19.

The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19. According to a June 2022 study, COVID‑19 vaccines prevented an additional 14.4 to 19.8 million deaths in 185 countries and territories from 8 December 2020 to 8 December 2021. Many countries implemented phased distribution plans that prioritized those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers.

Common side effects of COVID‑19 vaccines include soreness, redness, rash, inflammation at the injection site, fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), which resolve without medical treatment within a few days. COVID-19 vaccination is safe for people who are breastfeeding.

As of 30 April 2023, 13.38 billion doses of COVID‑19 vaccines have been administered worldwide based on official reports from national public health agencies. By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of the doses purchased by high-income countries comprising 14% of the world's population. Despite the extremely rapid development of effective mRNA and viral vector vaccines, worldwide vaccine equity has not been achieved. The development and use of whole inactivated virus (WIV) and protein-based vaccines have also been recommended, especially for use in developing countries. The United States Food and Drug Administration (FDA) has now authorized bivalent vaccines to protect against the original COVID-19 strain and its Omicron variant.

Background

• 

  COVID‑19 vaccine doses administered by continent as of October 11, 2021. For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses can be higher than the number of people in the population.

• 

  Map showing share of population fully vaccinated against COVID-19 relative to a country's total population

A US airman receiving a COVID‑19 vaccine, December 2020

Map of countries by approval status

  Approved for general use, mass vaccination underway

  EUA (or equivalent) granted, mass vaccination underway

  EUA granted, mass vaccination planned

  No data available

Prior to COVID‑19, a vaccine for an infectious disease had never been produced in less than several years – and no vaccine existed for preventing a coronavirus infection in humans. However, vaccines have been produced against several animal diseases caused by coronaviruses, including (as of 2003) infectious bronchitis virus in birds, canine coronavirus, and feline coronavirus. Previous projects to develop vaccines for viruses in the family Coronaviridae that affect humans have been aimed at severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Vaccines against SARS and MERS have been tested in non-human animals.

According to studies published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world at that time. There is no cure or protective vaccine proven to be safe and effective against SARS in humans. There is also no proven vaccine against MERS. When MERS became prevalent, it was believed that existing SARS research might provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection. As of March 2020, there was one (DNA-based) MERS vaccine which completed Phase I clinical trials in humans, and three others in progress, all being viral-vectored vaccines: two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA-vectored (MVA-MERS-S).

Vaccines that use an inactive or weakened virus that has been grown in eggs typically take more than a decade to develop. In contrast, mRNA is a molecule that can be made quickly, and research on mRNA to fight diseases was begun decades before the COVID‑19 pandemic by scientists such as Drew Weissman and Katalin Karikó, who tested on mice. Moderna began human testing of an mRNA vaccine in 2015.Viral vector vaccines were also developed for the COVID‑19 pandemic after the technology was previously cleared for Ebola.

As multiple COVID‑19 vaccines have been authorized or licensed for use, real-world vaccine effectiveness (RWE) is being assessed using case control and observational studies. A study is investigating the long-lasting protection against SARS-CoV-2 provided by the mRNA vaccines.

Vaccine technologies

Conceptual diagram showing three vaccine types for forming SARS‑CoV‑2 proteins to prompt an immune response: (1) RNA vaccine, (2) subunit vaccine, (3) viral vector vaccine

Vaccine platforms being employed for SARS-CoV-2. Whole virus vaccines include both attenuated and inactivated forms of the virus. Protein and peptide subunit vaccines are usually combined with an adjuvant in order to enhance immunogenicity. The main emphasis in SARS-CoV-2 vaccine development has been on using the whole spike protein in its trimeric form, or components of it, such as the RBD region. Multiple non-replicating viral vector vaccines have been developed, particularly focused on adenovirus, while there has been less emphasis on the replicating viral vector constructs.

As of July 2021, at least nine different technology platforms are under research and development to create an effective vaccine against COVID‑19. Most of the platforms of vaccine candidates in clinical trials are focused on the coronavirus spike protein (S protein) and its variants as the primary antigen of COVID‑19 infection, since the S protein triggers strong B-cell and T-cell immune responses. However, other coronavirus proteins are also being investigated for vaccine development, like the nucleocapsid, because they also induce a robust T-cell response and their genes are more conserved and recombine less frequently (compared to Spike). Future generations of COVID-19 vaccines that may target more and conserved genomic regions will also act as an insurance against the manifestation of catastrophic scenarios concerning the future evolutionary path of SARS-CoV-2, or any similar Coronavirus epidemic/pandemic.

Platforms developed in 2020 involved nucleic acid technologies (nucleoside-modified messenger RNA and DNA), non-replicating viral vectors, peptides, recombinant proteins, live attenuated viruses, and inactivated viruses.

Many vaccine technologies being developed for COVID‑19 are not like influenza vaccines, but rather are using "next-generation" strategies for precise targeting of COVID‑19 infection mechanisms. Several of the synthetic vaccines use a 2P mutation to lock the spike protein into its prefusion configuration, stimulating an adaptive immune response to the virus before it attaches to a human cell. Vaccine platforms in development may improve flexibility for antigen manipulation, and effectiveness for targeting mechanisms of COVID‑19 infection in susceptible population subgroups, such as healthcare workers, the elderly, children, pregnant women, and people with weakened immune systems.

mRNA vaccines

Diagram of the operation of an RNA vaccine. Messenger RNA contained in the vaccine enters cells and is translated into foreign proteins, which trigger an immune response.

Several COVID‑19 vaccines, such as the Pfizer–BioNTech and Moderna vaccines, use RNA to stimulate an immune response. When introduced into human tissue, the vaccine contains either self-replicating RNA or messenger RNA (mRNA), which both cause cells to express the SARS-CoV-2 spike protein. This teaches the body how to identify and destroy the corresponding pathogen. RNA vaccines often use nucleoside-modified messenger RNA. The delivery of mRNA is achieved by a coformulation of the molecule into lipid nanoparticles which protect the RNA strands and help their absorption into the cells.

RNA vaccines are the first COVID‑19 vaccines to be authorized in the United Kingdom, the United States and the European Union. Authorized vaccines of this type are the Pfizer–BioNTech and Moderna vaccines. The CVnCoV RNA vaccine from CureVac failed in clinical trials.

Severe allergic reactions are rare. In December 2020, 1,893,360 first doses of Pfizer–BioNTech COVID‑19 vaccine administration resulted in 175 cases of severe allergic reaction, of which 21 were anaphylaxis. For 4,041,396 Moderna COVID‑19 vaccine dose administrations in December 2020 and January 2021, only ten cases of anaphylaxis were reported.Lipid nanoparticles (LNPs) were most likely responsible for the allergic reactions.

Adenovirus vector vaccines

These vaccines are examples of non-replicating viral vector vaccines, using an adenovirus shell containing DNA that encodes a SARS‑CoV‑2 protein. The viral vector-based vaccines against COVID‑19 are non-replicating, meaning that they do not make new virus particles, but rather produce only the antigen which elicits a systemic immune response.

Authorized vaccines of this type are the Oxford–AstraZeneca COVID‑19 vaccine, the Sputnik V COVID‑19 vaccine,Convidecia, and the Janssen COVID‑19 vaccine.

Convidecia and Janssen are both one-shot vaccines which offer less complicated logistics and can be stored under ordinary refrigeration for several months.

Sputnik V uses Ad26 for its first dose, which is the same as Janssen's only dose, and Ad5 for the second dose, which is the same as Convidecia's only dose.

In August 2021, the developers of Sputnik V proposed, in view of the Delta case surge, that Pfizer test the Ad26 component (termed its 'Light' version) as a booster shot.

Inactivated virus vaccines

Inactivated vaccines consist of virus particles that are grown in culture and then killed using a method such as heat or formaldehyde to lose disease-producing capacity, while still stimulating an immune response.

Authorized vaccines of this type are the Chinese CoronaVac and the Sinopharm BIBP and WIBP vaccines; the Indian Covaxin; later this year the Russian CoviVac; the Kazakh vaccine QazVac; and the Iranian COVIran Barekat. Vaccines in clinical trials include the Valneva COVID‑19 vaccine.

Subunit vaccines

Subunit vaccines present one or more antigens without introducing whole pathogen particles. The antigens involved are often protein subunits, but can be any molecule fragment of the pathogen.

The authorized vaccines of this type are Novavax COVID‑19 vaccine, the peptide vaccine EpiVacCorona,ZF2001,MVC-COV1901,Corbevax, the Sanofi–GSK vaccine, and Soberana 02 (a conjugate vaccine).Bimervax was approved for use as a booster vaccine in the European Union in March 2023.

The V451 vaccine was in clinical trials that were terminated after it was found that the vaccine may potentially cause incorrect results for subsequent HIV testing.

Other types

Additional types of vaccines that are in clinical trials include virus-like particle vaccines, multiple DNA plasmid vaccines, at least two lentivirus vector vaccines, a conjugate vaccine, and a vesicular stomatitis virus displaying the SARS‑CoV‑2 spike protein.

Scientists investigated whether existing vaccines for unrelated conditions could prime the immune system and lessen the severity of COVID‑19 infections. There is experimental evidence that the BCG vaccine for tuberculosis has non-specific effects on the immune system, but no evidence that this vaccine is effective against COVID‑19.

List of authorized vaccines

Delivery methods

All coronavirus vaccines are administrated by injection. However, various other types of vaccine delivery methods have been studied for future coronavirus vaccines.

Intranasal

Intranasal vaccines target mucosal immunity in the nasal mucosa which is a portal for viral entrance to the body. These vaccines are designed to stimulate nasal immune factors, such as IgA. In addition to inhibiting the virus, nasal vaccines provide ease of administration because no needles (or needle phobia) are involved. Nasal vaccines have been approved for influenza, but not for COVID-19.

A variety of intranasal COVID-19 vaccines are undergoing clinical trials. One is in use in China. Examples include a vaccine candidate which uses a modified avian virus as a vector to target SARS-CoV-2 spike proteins and an mRNA vaccine delivered via a nasal nanoparticle spray. In September 2022, India and China approved the two first nasal COVID-19 vaccines (iNCOVACC and Convidecia) which may (as boosters) also reduce transmission (potentially via sterilizing immunity).

Autologous

Aivita Biomedical is developing an experimental autologous dendritic cell COVID‑19 vaccine kit where the vaccine is prepared and incubated at the point-of-care using cells from the intended recipient. The vaccine is undergoing small phase I and phase II clinical studies.

Universal vaccine

A universal coronavirus vaccine would be effective against all coronavirus (and possibly other) viruses. The concept was publicly endorsed by NIAID director Anthony Fauci, virologist Jeffery K. Taubenberger, and David M. Morens. In March 2022, the White House released the "National COVID-19 Preparedness Plan", which recommended accelerating development of a universal coronavirus vaccine.

One attempt at such a vaccine is being developed at Walter Reed Army Institute of Research. It uses a spike ferritin-based nanoparticle (SpFN). This vaccine began a Phase I clinical trial in April 2022.

Another strategy is to attach vaccine fragments from multiple strains to a nanoparticle scaffold. Universality is enhanced by targeting the receptor-binding domain rather than the spike protein.

Formulation

As of September 2020, eleven of the vaccine candidates in clinical development use adjuvants to enhance immunogenicity. An immunological adjuvant is a substance formulated with a vaccine to elevate the immune response to an antigen, such as the COVID‑19 virus or influenza virus. Specifically, an adjuvant may be used in formulating a COVID‑19 vaccine candidate to boost its immunogenicity and efficacy to reduce or prevent COVID‑19 infection in vaccinated individuals. Adjuvants used in COVID‑19 vaccine formulation may be particularly effective for technologies using the inactivated COVID‑19 virus and recombinant protein-based or vector-based vaccines. Aluminum salts, known as "alum", were the first adjuvant used for licensed vaccines, and are the adjuvant of choice in some 80% of adjuvanted vaccines. The alum adjuvant initiates diverse molecular and cellular mechanisms to enhance immunogenicity, including release of proinflammatory cytokines.

Planning and development

Since January 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments.

Multiple steps along the entire development path are evaluated, including:

• the level of acceptable toxicity of the vaccine (its safety),
• targeting vulnerable populations,
• the need for vaccine efficacy breakthroughs,
• the duration of vaccination protection,
• special delivery systems (such as oral or nasal, rather than by injection),
• dose regimen,
• stability and storage characteristics,
• emergency use authorization before formal licensing,
• optimal manufacturing for scaling to billions of doses, and
• dissemination of the licensed vaccine.

Challenges

There have been several unique challenges with COVID‑19 vaccine development.

Public health programs have been described as in "[a] race to vaccinate individuals" with the early wave vaccines.

Timelines for conducting clinical research – normally a sequential process requiring years – are being compressed into safety, efficacy, and dosing trials running simultaneously over months, potentially compromising safety assurance. For example, Chinese vaccine developers and the government Chinese Center for Disease Control and Prevention began their efforts in January 2020, and by March were pursuing numerous candidates on short timelines.

The rapid development and urgency of producing a vaccine for the COVID‑19 pandemic was expected to increase the risks and failure rate of delivering a safe, effective vaccine. Additionally, research at universities is obstructed by physical distancing and closing of laboratories.

Vaccines must progress through several phases of clinical trials to test for safety, immunogenicity, effectiveness, dose levels and adverse effects of the candidate vaccine. Vaccine developers have to invest resources internationally to find enough participants for Phase II–III clinical trials when the virus has proved to be a "moving target" of changing transmission rates across and within countries, forcing companies to compete for trial participants.

Clinical trial organizers also may encounter people unwilling to be vaccinated due to vaccine hesitancy or disbelief in the science of the vaccine technology and its ability to prevent infection. As new vaccines are developed during the COVID‑19 pandemic, licensure of COVID‑19 vaccine candidates requires submission of a full dossier of information on development and manufacturing quality.

Organizations

Internationally, the Access to COVID‑19 Tools Accelerator is a G20 and World Health Organization (WHO) initiative announced in April 2020. It is a cross-discipline support structure to enable partners to share resources and knowledge. It comprises four pillars, each managed by two to three collaborating partners: Vaccines (also called "COVAX"), Diagnostics, Therapeutics, and Health Systems Connector. The WHO's April 2020 "R&D Blueprint (for the) novel Coronavirus" documented a "large, international, multi-site, individually randomized controlled clinical trial" to allow "the concurrent evaluation of the benefits and risks of each promising candidate vaccine within 3–6 months of it being made available for the trial." The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase III protocols for all vaccines achieving the pivotal trial stage.

National governments have also been involved in vaccine development. Canada announced funding of 96 projects for development and production of vaccines at Canadian companies and universities with plans to establish a "vaccine bank" that could be used if another coronavirus outbreak occurs, and to support clinical trials and develop manufacturing and supply chains for vaccines.

China provided low-rate loans to one vaccine developer through its central bank, and "quickly made land available for the company" to build production plants. Three Chinese vaccine companies and research institutes are supported by the government for financing research, conducting clinical trials, and manufacturing.

The United Kingdom government formed a COVID‑19 vaccine task force in April 2020 to stimulate local efforts for accelerated development of a vaccine through collaborations of industry, universities, and government agencies. The UK's Vaccine Taskforce contributed to every phase of development from research to manufacturing.

In the United States, the Biomedical Advanced Research and Development Authority (BARDA), a federal agency funding disease-fighting technology, announced investments to support American COVID‑19 vaccine development, and manufacture of the most promising candidates. In May 2020, the government announced funding for a fast-track program called Operation Warp Speed. By March 2021, BARDA had funded an estimated $19.3 billion in COVID‑19 vaccine development.

Large pharmaceutical companies with experience in making vaccines at scale, including Johnson & Johnson, AstraZeneca, and GlaxoSmithKline (GSK), formed alliances with biotechnology companies, governments, and universities to accelerate progression toward effective vaccines.

Clinical research

Post-vaccination complications

History

COVID‑19 vaccine research samples in a NIAID lab freezer (30 January 2020)

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering the urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

In February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS‑CoV‑2 to become available in less than 18 months. Virologist Paul Offit commented that, in hindsight, the development of a safe and effective vaccine within 11 months was a remarkable feat. The rapidly growing infection rate of COVID‑19 worldwide during 2020 stimulated international alliances and government efforts to urgently organize resources to make multiple vaccines on shortened timelines, with four vaccine candidates entering human evaluation in March (see COVID-19 vaccine § Trial and authorization status).

On 24 June 2020, China approved the CanSino vaccine for limited use in the military, and two inactivated virus vaccines for emergency use in high-risk occupations. On 11 August 2020, Russia announced the approval of its Sputnik V vaccine for emergency use, though one month later only small amounts of the vaccine had been distributed for use outside of the phase 3 trial.

The Pfizer–BioNTech partnership submitted an Emergency Use Authorization (EUA) request to the U.S. Food and Drug Administration (FDA) for the mRNA vaccine BNT162b2 (active ingredient tozinameran) on 20 November 2020. On 2 December 2020, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) gave temporary regulatory approval for the Pfizer–BioNTech vaccine, becoming the first country to approve the vaccine and the first country in the Western world to approve the use of any COVID‑19 vaccine. As of 21 December 2020, many countries and the European Union had authorized or approved the Pfizer–BioNTech COVID‑19 vaccine. Bahrain and the United Arab Emirates granted emergency marketing authorization for the Sinopharm BIBP vaccine. On 11 December 2020, the FDA granted an EUA for the Pfizer–BioNTech COVID‑19 vaccine. A week later, they granted an EUA for mRNA-1273 (active ingredient elasomeran), the Moderna vaccine.

On 31 March 2021, the Russian government announced that they had registered the first COVID‑19 vaccine for animals. Named Carnivac-Cov, it is an inactivated vaccine for carnivorous animals, including pets, aimed at preventing mutations that occur during the interspecies transmission of SARS-CoV-2.

In October 2022 China began administering an oral vaccine developed by CanSino Bioligics, using its adenovirus model.

Despite the availability of mRNA and viral vector vaccines, worldwide vaccine equity has not been achieved. The ongoing development and use of whole inactivated virus (WIV) and protein-based vaccines has been recommended, especially for use in developing countries, to dampen further waves of the pandemic.

In November 2021, the full nucleotide sequences of the AstraZeneca and Pfizer/BioNTech vaccines were released by the UK Medicines and Healthcare products Regulatory Agency, in response to a freedom of information request.

Effectiveness

Duration of immunity

As of 2021, available evidence shows that fully vaccinated individuals and those previously infected with SARS-CoV-2 have a low risk of subsequent infection for at least six months. There is insufficient data to determine an antibody titer threshold that indicates when an individual is protected from infection. Multiple studies show that antibody titers are associated with protection at the population level, but individual protection titers remain unknown. For some populations, such as the elderly and the immunocompromised, protection levels may be reduced after both vaccination and infection. Available evidence indicates that the level of protection may not be the same for all variants of the virus.

As of December 2021, there are no FDA-authorized or approved tests that providers or the public can use to determine if a person is protected from infection reliably.

As of March 2022, elderly residents' protection against severe illness, hospitalization and death in English care homes was high immediately after vaccination, but protection declined significantly in the months following vaccination. Protection among care home staff, who were younger, declined much more slowly. Regular boosters are recommended for older people, and boosters for care home residents every six months appear reasonable.

The US Centers for Disease Control and Prevention (CDC) recommends a fourth dose of the Pfizer mRNA vaccine as of March 2022, for "certain immunocompromised individuals and people over the age of 50".

Immune evasion by variants

In contrast to other investigated prior variants, the SARS-CoV-2 Omicron variant and its BA.4/5 subvariants have evaded immunity induced by vaccines, which may lead to breakthrough infections despite recent vaccination. Nevertheless, vaccines are thought to provide protection against severe illness, hospitalizations, and deaths due to Omicron.

Vaccine adjustments

Effectiveness against transmission

As of 2022, fully vaccinated individuals with breakthrough infections with SARS-CoV-2 delta (B.1.617.2) variant have peak viral load similar to unvaccinated cases and can transmit infection in household settings.

Mix and match

According to studies, the combination of two different COVID‑19 vaccines, also called cross vaccination or mix-and-match method, provides protection equivalent to that of mRNA vaccines – including protection against the Delta variant. Individuals who receive the combination of two different vaccines produce strong immune responses, with side effects no worse than those caused by standard regimens.

Adverse events

For most people, the side effects, also called adverse effects, from COVID‑19 vaccines are mild and can be managed at home. Adverse effects of the COVID-19 vaccination are similar to other vaccines, and severe adverse effects are rare. Adverse effects from the vaccine are higher than placebo, but placebo arms of vaccine trials still reported adverse effects that can be attributed to the nocebo effect.

All vaccines that are administered via intramuscular injection, including COVID‑19 vaccines, have side effects related to the mild trauma associated with the procedure and introduction of a foreign substance into the body. These include soreness, redness, rash, and inflammation at the injection site. Other common side effects include fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), all of which generally resolve without medical treatment within a few days. Like any other vaccine, some people are allergic to one or more ingredients in COVID‑19 vaccines. Typical side effects are stronger and more common in younger people and in subsequent doses, and up to 20% of people report a disruptive level of side effects after the second dose of an mRNA vaccine. These side effects are less common or weaker in inactivated vaccines. Covid-19 vaccination related enlargement of lymph node happens in 11.6% of those who received one dose of vaccine and in 16% of those received two doses.

Experiments in mice show that intramuscular injections of lipid excipient nanoparticles (inactive substance that serves as the vehicle or medium) causes particles to enter the blood plasma and many organs with higher concentrations found in the liver, and lower concentrations in the spleen, adrenal glands, and ovaries. The highest concentration of nanoparticles was found at the injection site itself.

COVID‑19 vaccination is safe for breastfeeding people. Temporary changes to the menstrual cycle in young women have been reported. However, these changes are "small compared with natural variation and quickly reverse". In one study, women who received both doses of a two-dose vaccine during the same menstrual cycle (an atypical situation) may see their next period begin a couple of days late. They have about twice the usual risk of a clinically significant delay (about 10% of these women, compared to about 4% of unvaccinated women). Cycle lengths return to normal after two menstrual cycles post-vaccination. Women who received doses in separate cycles had approximately the same natural variation in cycle lengths as unvaccinated women. Other temporary menstrual effects have been reported, such as heavier than normal menstrual bleeding after vaccination.

Serious adverse events associated COVID‑19 vaccines are generally rare but of high interest to the public. The official databases of reported adverse events include the World Health Organization's VigiBase, the United States Vaccine Adverse Events Reporting System (VAERS) and the United Kingdom's Yellow Card Scheme. Increased public awareness of these reporting systems and the extra reporting requirements under US FDA Emergency Use Authorization rules have increased reported adverse events. Serious side effects are an ongoing area of study, and resources have been allocated to try and better understand them. Rsearch currently indicates that the rate and type of side effects are lower risk then infection. For example, although vaccination may trigger some side effects, the effects experienced from an infection could be worse. Neurological side effects from getting COVID-19 are hundreds of times more likely than from vaccination.

Documented rare serious effects include:

• anaphylaxis, a severe type of allergic reaction. Anaphylaxis affects one person per 250,000 to 400,000 doses administered.
• blood clots (thrombosis). These vaccine-induced immune thrombocytopenia and thrombosis are associated with vaccines using an adenovirus system (Janssen and Oxford-AstraZeneca). These affect about one person per 100,000.
• myocarditis and pericarditis, or inflammation of the heart. There is a rare risk of myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the membrane covering the heart) after the mRNA COVID-19 vaccines (Moderna or Pfizer-BioNTech). The risk of myocarditis after COVID-19 vaccination is estimated to be 0.3 to 5 cases per 100,000 persons with the highest risk in young males. In an Israeli nation-wide population based study (in which the Pfizer-BioNTech vaccine was exclusively given), the incidence rate of myocarditis was 54 cases per 2.5 million vaccine recipients, with an overall incidence rate of 2 cases per 100,000 persons, with the highest incidence seen in young males (aged 16 to 29) at 10 cases per 100,000 vaccine recipients. Of the cases of myocarditis seen, 76% were mild in severity, with one case of cardiogenic shock (heart failure) and no deaths reported. COVID-19 vaccines may protect against myocarditis due to subsequent COVID-19 infection. The risk of myocarditis and pericarditis is significantly higher (up to 11 times higher with respect to myocarditis) after COVID-19 infection as compared to COVID-19 vaccination, with the possible exception of younger men (less than 40 years old) who may have a higher risk of myocarditis after the second Moderna mRNA vaccine (an additional 97 cases of myocarditis per 1 million persons vaccinated).
• thrombotic thrombocytopenia and other autoimmune diseases, which have been reported as adverse events after COVID-19 vaccine.

There are rare reports of subjective hearing changes, including tinnitus, after vaccination.

Society and culture

Distribution

Note about table in this section: Number and percentage of people who have received at least one dose of a COVID‑19 vaccine (unless noted otherwise). May include vaccination of non-citizens, which can push totals beyond 100% of the local population. Table is updated daily by a bot.

• v
• t
• e

[expand]

[collapse]

Updated May 16, 2023.

COVID-19 vaccine distribution by country

	Location	Vaccinated	Percent
	World	5,581,487,279	69.99%
	China	1,310,292,000	91.89%
	India	1,027,406,254	72.50%
	European Union	338,197,166	75.13%
	United States	270,227,181	81.39%
	Indonesia	203,657,535	73.92%
	Brazil	189,643,431	88.08%
	Pakistan	165,538,888	70.20%
	Bangladesh	151,323,679	88.40%
	Japan	104,705,133	84.47%
	Mexico	97,179,493	76.22%
	Vietnam	90,253,541	91.92%
	Russia	88,801,011	61.36%
	Nigeria	82,325,196	37.67%
	Philippines	78,484,848	67.92%
	Iran	65,174,475	73.60%
	Germany	64,876,299	77.82%
	Turkey	57,941,051	67.89%
	Thailand	57,005,497	79.62%
	Egypt	56,709,060	51.09%
	France	54,673,567	80.62%
	United Kingdom	53,806,963	79.97%
	Italy	50,895,761	86.21%
	South Korea	44,786,692	86.43%
	Ethiopia	44,073,766	35.72%
	Colombia	43,012,174	82.92%
	Argentina	41,491,363	91.17%
	Spain	41,349,325	86.94%
	Myanmar	34,777,314	64.64%
	Canada	34,763,194	90.40%
	Tanzania	34,434,933	52.57%
	Peru	30,485,522	89.53%
	Malaysia	28,135,490	82.90%
	Nepal	27,794,462	90.99%
	Saudi Arabia	27,041,364	74.27%
	Morocco	25,020,092	66.80%
	South Africa	24,165,157	40.35%
	Poland	22,875,338	57.39%
	Australia	22,236,698	84.95%
	Venezuela	22,157,232	78.29%
	Taiwan	21,885,289	91.60%
	Uzbekistan	21,674,823	62.59%
	Mozambique	19,939,353	60.48%
	Uganda	19,488,104	41.25%
	Chile	18,088,517	92.27%
	Sri Lanka	17,143,761	78.53%
	Angola	15,745,756	44.24%
	Ukraine	15,729,617	36.19%
	Democratic Republic of the Congo	15,388,889	15.54%
	Ecuador	15,333,873	85.18%
	Cambodia	15,285,834	91.16%
	Sudan	15,207,452	32.44%
	Afghanistan	14,823,235	36.04%
	Kenya	14,494,372	26.83%
	Ivory Coast	13,568,372	48.18%
	Ghana	13,221,421	39.50%
	Netherlands	12,775,557	73.00%
	Zambia	11,637,730	58.14%
	Iraq	11,332,925	25.47%
	Kazakhstan	10,858,101	55.98%
	Cuba	10,737,736	95.77%
	Rwanda	10,572,981	76.75%
	United Arab Emirates	9,991,089	100.00%
	Portugal	9,784,298	95.26%
	Belgium	9,266,477	79.50%
	Guatemala	8,930,737	50.05%
	Somalia	8,370,355	47.57%
	Romania	8,187,261	41.65%
	Greece	7,935,166	76.41%
	Algeria	7,840,131	17.75%
	Sweden	7,775,726	73.71%
	Guinea	7,679,918	55.41%
	Bolivia	7,361,008	60.94%
	Dominican Republic	7,318,829	65.18%
	Tunisia	7,218,536	58.42%
	Czech Republic	6,976,554	66.48%
	Hong Kong	6,916,009	92.35%
	Austria	6,899,577	77.18%
	Israel	6,723,119	71.15%
	Honduras	6,551,299	62.79%
	Belarus	6,527,591	68.46%
	Zimbabwe	6,437,808	40.25%
	Hungary	6,420,813	64.42%
	Nicaragua	6,260,823	90.10%
	Chad	6,254,729	35.29%
	Niger	6,217,508	23.72%
	Switzerland	6,096,788	69.75%
	Laos	5,888,649	79.31%
	Azerbaijan	5,373,253	52.10%
	Tajikistan	5,282,863	54.18%
	Malawi	5,205,668	25.51%
	Singapore	5,160,551	91.55%
	Burkina Faso	5,152,110	22.72%
	Sierra Leone	5,113,414	59.42%
	Jordan	4,821,579	43.25%
	Denmark	4,776,585	81.20%
	El Salvador	4,652,597	73.69%
	Costa Rica	4,630,486	89.38%
	Finland	4,524,418	81.66%
	Norway	4,346,995	79.99%
	New Zealand	4,301,605	82.96%
	Mali	4,271,977	18.91%
	South Sudan	4,262,480	39.06%
	Republic of Ireland	4,108,460	81.79%
	Paraguay	3,989,519	58.84%
	Liberia	3,825,381	72.14%
	Benin	3,697,190	27.69%
	Cameroon	3,656,503	13.10%
	Panama	3,531,965	80.12%
	Kuwait	3,456,926	80.98%
	Serbia	3,354,075	48.81%
	Syria	3,295,630	14.90%
	Oman	3,257,365	71.18%
	Uruguay	3,009,691	87.93%
	Qatar	2,852,178	105.83%
	Slovakia	2,822,919	51.82%
	Lebanon	2,740,227	49.92%
	Senegal	2,684,696	15.50%
	Madagascar	2,569,590	8.68%
	Central African Republic	2,381,935	42.69%
	Croatia	2,321,595	57.60%
	Libya	2,316,327	34.00%
	Mongolia	2,272,965	68.27%
	Togo	2,246,404	25.39%
	Bulgaria	2,107,140	31.07%
	Mauritania	2,101,025	44.36%
	Palestine	2,012,767	38.34%
	Lithuania	1,957,146	71.17%
	Botswana	1,951,054	74.18%
	Kyrgyzstan	1,676,505	25.28%
	Georgia	1,654,504	44.03%
	Albania	1,347,054	47.39%
	Latvia	1,346,184	71.84%
	Slovenia	1,265,802	59.72%
	Bahrain	1,241,174	84.31%
	Armenia	1,128,072	38.01%
	Mauritius	1,123,773	86.48%
	Moldova	1,108,063	33.85%
	Yemen	1,032,545	3.06%
	Lesotho	1,014,073	43.98%
	Bosnia and Herzegovina	943,394	28.91%
	Gambia	934,799	34.55%
	Kosovo	906,858	50.89%
	Timor-Leste	883,812	65.89%
	Estonia	869,333	65.56%
	Jamaica	857,579	30.33%
	North Macedonia	854,392	40.81%
	Trinidad and Tobago	753,588	49.39%
	Guinea-Bissau	733,271	34.83%
	Fiji	712,025	76.58%
	Bhutan	699,116	89.35%
	Republic of the Congo	695,760	11.92%
	Macau	679,703	97.77%
	Cyprus	670,969	74.88%
	Namibia	616,288	24.01%
	Eswatini	526,050	43.78%
	Guyana	495,285	61.24%
	Luxembourg	481,957	74.42%
	Malta	478,776	89.78%
	Haiti	465,761	4.02%
	Brunei	451,032	100.45%
	Comoros	438,825	53.41%
	Maldives	399,304	76.23%
	Papua New Guinea	382,020	3.77%
	Djibouti	372,077	33.20%
	Cabo Verde	356,734	60.68%
	Solomon Islands	343,821	47.47%
	Gabon	311,040	13.02%
	Iceland	309,770	84.00%
	Northern Cyprus	301,673	78.80%
	Montenegro	292,783	46.63%
	Equatorial Guinea	270,109	16.53%
	Suriname	267,820	45.26%
	Belize	258,473	63.78%
	New Caledonia	192,375	66.35%
	Samoa	191,403	86.07%
	French Polynesia	190,908	62.33%
	Vanuatu	176,624	54.06%
	Bahamas	174,147	42.48%
	Barbados	163,845	58.17%
	Sao Tome and Principe	140,256	61.68%
	Curaçao	108,601	56.81%
	Kiribati	100,900	76.88%
	Aruba	90,433	84.95%
	Seychelles	88,520	82.62%
	Tonga	87,342	81.73%
	Jersey	84,365	76.14%
	Isle of Man	69,560	81.44%
	Antigua and Barbuda	64,290	68.97%
	Cayman Islands	62,023	90.25%
	Saint Lucia	60,140	33.43%
	Andorra	57,901	72.52%
	Guernsey	54,223	85.62%
	Bermuda	48,554	75.65%
	Grenada	44,241	35.26%
	Gibraltar	42,175	129.07%
	Faroe Islands	41,715	85.04%
	Greenland	41,243	72.52%
	Saint Vincent and the Grenadines	37,527	36.10%
	Burundi	35,150	0.27%
	Saint Kitts and Nevis	33,794	70.88%
	Dominica	32,995	45.57%
	Turks and Caicos Islands	32,815	71.76%
	Turkmenistan	32,240	0.53%
	Sint Maarten	29,788	67.41%
	Liechtenstein	26,771	68.02%
	Monaco	26,672	67.49%
	San Marino	26,357	77.50%
	British Virgin Islands	19,466	62.55%
	Caribbean Netherlands	19,109	72.26%
	Cook Islands	15,112	88.73%
	Nauru	13,106	103.27%
	Anguilla	10,854	68.36%
	Wallis and Futuna	7,150	61.66%
	Tuvalu	6,368	53.40%
	Saint Helena, Ascension and Tristan da Cunha	4,361	71.83%
	Falkland Islands	2,632	75.57%
	Tokelau	2,203	116.38%
	Montserrat	2,104	47.68%
	Niue	1,650	102.23%
	Pitcairn Islands	47	100.00%
	North Korea	0	0.00%

Access

Countries have extremely unequal access to the COVID-19 vaccine. Vaccine equity has not been achieved or even approximated. The inequity has harmed both countries with poor access and countries with good access.

Nations pledged to buy doses of the COVID‑19 vaccines before the doses were available. Though high-income nations represent only 14% of the global population, as of 15 November 2020, they had contracted to buy 51% of all pre-sold doses. Some high-income nations bought more doses than would be necessary to vaccinate their entire populations.

Production of Sputnik V vaccine in Brazil, January 2021

An elderly man receiving second dose of CoronaVac vaccine in Brazil, April 2021

Covid vaccination for children aged 12–14 in Bhopal, India

In January 2021, WHO Director-General Tedros Adhanom Ghebreyesus warned of problems with equitable distribution: "More than 39 million doses of vaccine have now been administered in at least 49 higher-income countries. Just 25 doses have been given in one lowest-income countries. Not 25 million; not 25 thousand; just 25."

In March 2021, it was revealed the US attempted to convince Brazil not to purchase the Sputnik V COVID‑19 vaccine, fearing "Russian influence" in Latin America. Some nations involved in long-standing territorial disputes have reportedly had their access to vaccines blocked by competing nations; Palestine has accused Israel of blocking vaccine delivery to Gaza, while Taiwan has suggested that China has hampered its efforts to procure vaccine doses.

A single dose of the COVID‑19 vaccines by AstraZeneca would cost 47 Egyptian pounds (EGP), and the authorities are selling it between 100 and 200 EGP. A report by Carnegie Endowment for International Peace cited the poverty rate in Egypt as around 29.7 percent, which constitutes approximately 30.5 million people, and claimed that about 15 million of Egyptians would be unable to gain access to the luxury of vaccination. A human rights lawyer, Khaled Ali, launched a lawsuit against the government, forcing them to provide vaccination free of cost to all members of the public.

According to immunologist Anthony Fauci, mutant strains of the virus and limited vaccine distribution pose continuing risks and he said: "we have to get the entire world vaccinated, not just our own country." Edward Bergmark and Arick Wierson are calling for a global vaccination effort and wrote that the wealthier nations' "me-first" mentality could ultimately backfire because the spread of the virus in poorer countries would lead to more variants, against which the vaccines could be less effective.

In March 2021, the United States, Britain, European Union member states and some other members of the World Trade Organization (WTO) blocked a push by more than eighty developing countries to waive COVID‑19 vaccine patent rights in an effort to boost production of vaccines for poor nations. On 5 May 2021, the US government under President Joe Biden announced that it supports waiving intellectual property protections for COVID‑19 vaccines. The Members of the European Parliament have backed a motion demanding the temporary lifting of intellectual properties rights for COVID‑19 vaccines.

COVID‑19 mass vaccination queue in Finland, June 2021

A drive-through COVID‑19 vaccination center in Iran, August 2021

In a meeting in April 2021, the World Health Organization's emergency committee addressed concerns of persistent inequity in the global vaccine distribution. Although 9 percent of the world's population lives in the 29 poorest countries, these countries had received only 0.3% of all vaccines administered as of May 2021. In March 2021, Brazilian journalism agency Agência Pública reported that the country vaccinated about twice as many people who declare themselves white than black and noted that mortality from COVID‑19 is higher in the black population.

In May 2021, UNICEF made an urgent appeal to industrialized nations to pool their excess COVID‑19 vaccine capacity to make up for a 125-million-dose gap in the COVAX program. The program mostly relied on the Oxford–AstraZeneca COVID‑19 vaccine produced by Serum Institute of India, which faced serious supply problems due to increased domestic vaccine needs in India from March to June 2021. Only a limited amount of vaccines can be distributed efficiently, and the shortfall of vaccines in South America and parts of Asia are due to a lack of expedient donations by richer nations. International aid organizations have pointed at Nepal, Sri Lanka, and Maldives as well as Argentina and Brazil, and some parts of the Caribbean as problem areas, where vaccines are in short supply. In mid-May 2021, UNICEF was also critical of the fact that most proposed donations of Moderna and Pfizer vaccines were not slated for delivery until the second half of 2021, or early in 2022.

In July 2021, the heads of the World Bank Group, the International Monetary Fund, the World Health Organization, and the World Trade Organization said in a joint statement: "As many countries are struggling with new variants, and a third wave of COVID‑19 infections, accelerating access to vaccines becomes even more critical to ending the pandemic everywhere and achieving broad-based growth. We are deeply concerned about the limited vaccines, therapeutics, diagnostics, and support for deliveries available to developing countries." In July 2021, The BMJ reported that countries have thrown out over 250,000 vaccine doses as supply exceeded demand and strict laws prevented the sharing of vaccines. A survey by The New York Times found that over a million doses of vaccine had been thrown away in ten U.S. states because federal regulations prohibit recalling them, preventing their redistribution abroad. Furthermore, doses donated close to expiration often cannot be administered quickly enough by recipient countries and end up having to be discarded. To help overcome this problem, the Prime Minister of India, Narendra Modi announced that they would make their digital vaccination management platform CoWIN open to the global community. He also announced that India would also release the source code for the contact tracing app Aarogya Setu for developers around the world. Around 142 countries including Afghanistan, Bangladesh, Bhutan, Maldives, Guyana, Antigua & Barbuda, St. Kitts & Nevis and Zambia expressed their interest in the application for COVID management.

Amnesty International and Oxfam International have criticized the support of vaccine monopolies by the governments of producing countries, noting that this is dramatically increasing the dose price by five times and often much more, creating an economic barrier to access for poor countries.Médecins Sans Frontières (Doctors without Borders) has also criticized vaccine monopolies and repeatedly called from their suspension, supporting the TRIPS Waiver. The waiver was first proposed in October 2020 and has support from most countries, but delayed by opposition from EU (especially Germany – major EU countries such as France, Italy, and Spain support the exemption), UK, Norway, and Switzerland, among others. MSF called for a Day of Action in September 2021 to put pressure on the WTO Minister's meeting in November, which was expected to discuss the TRIPS IP waiver.

Inside of a vaccination center in Brussels, Belgium, February 2021

In August 2021, to reduce unequal distribution between rich and poor countries, the WHO called for a moratorium on a booster dose at least until the end of September. However, in August, the United States government announced plans to offer booster doses eight months after the initial course to the general population, starting with priority groups. Before the announcement, the WHO harshly criticized this type of a decision, citing the lack of evidence for the need for boosters, except for patients with specific conditions. At this time, vaccine coverage of at least one dose was 58% in high-income countries and only 1.3% in low-income countries, and 1.14 million Americans already received an unauthorized booster dose. US officials argued that waning efficacy against mild and moderate disease might indicate reduced protection against severe disease in the coming months. Israel, France, Germany, and the United Kingdom have also started planning boosters for specific groups. In September 2021, more than 140 former world leaders, and Nobel laureates, including former President of France François Hollande, former Prime Minister of the United Kingdom Gordon Brown, former Prime Minister of New Zealand Helen Clark, and Professor Joseph Stiglitz, called on the candidates to be the next German chancellor to declare themselves in favour of waiving intellectual property rules for COVID‑19 vaccines and transferring vaccine technologies. In November 2021, nursing unions in 28 countries have filed a formal appeal with the United Nations over the refusal of the UK, EU, Norway, Switzerland, and Singapore to temporarily waive patents for Covid vaccines.

During his first international trip, President of Peru Pedro Castillo spoke at the seventy-sixth session of the United Nations General Assembly on 21 September 2021, proposing the creation of an international treaty signed by world leaders and pharmaceutical companies to guarantee universal vaccine access, arguing "The battle against the pandemic has shown us the failure of the international community to cooperate under the principle of solidarity".

Optimizing the societal benefit of vaccination may benefit from a strategy that is tailored to the state of the pandemic, the demographics of a country, the age of the recipients, the availability of vaccines, and the individual risk for severe disease. In the UK, the interval between prime and boost dose was extended to vaccinate as many persons as early as possible, many countries are starting to give an additional booster shot to the immunosuppressed and the elderly, and research predicts an additional benefit of personalizing vaccine dose in the setting of limited vaccine availability when a wave of virus Variants of Concern hits a country.

Despite the extremely rapid development of effective mRNA and viral vector vaccines, vaccine equity has not been achieved. The World Health Organization called for 70 percent of the global population to be vaccinated by mid-2022, but as of March 2022, it was estimated that only one percent of the 10 billion doses given worldwide had been administered in low-income countries. An additional 6 billion vaccinations may be needed to fill vaccine access gaps, particularly in developing countries. Given the projected availability of newer vaccines, the development and use of whole inactivated virus (WIV) and protein-based vaccines are also recommended. Organizations such as the Developing Countries Vaccine Manufacturers Network could help to support the production of such vaccines in developing countries, with lower production costs and greater ease of deployment.

While vaccines substantially reduce the probability and severity of infection, it is still possible for fully vaccinated people to contract and spread COVID‑19. Public health agencies have recommended that vaccinated people continue using preventive measures (wear face masks, social distance, wash hands) to avoid infecting others, especially vulnerable people, particularly in areas with high community spread. Governments have indicated that such recommendations will be reduced as vaccination rates increase and community spread declines.

Economics

Moreover, an unequal distribution of vaccines will deepen inequality and exaggerate the gap between rich and poor and will reverse decades of hard-won progress on human development.
— United Nations, COVID vaccines: Widening inequality and millions vulnerable

Vaccine inequity damages the global economy, disrupting the global supply chain. Most vaccines were being reserved for wealthy countries, as of September 2021, some of which have more vaccine than is needed to vaccinate their populations fully. When people, under-vaccinated, needlessly die, experience disability, and live under lockdown restrictions, they cannot supply the same goods and services. This harms the economies of under-vaccinated and over-vaccinated countries alike. Since rich countries have larger economies, rich countries may lose more money to vaccine inequity than poor ones, though the poor ones will lose a higher percentage of GDP and experience longer-term effects. High-income countries would profit an estimated US$4.80 for every $1 spent on giving vaccines to lower-income countries.

The International Monetary Fund sees the vaccine divide between rich and poor nations as a serious obstacle to a global economic recovery. Vaccine inequity disproportionately affects refuge-providing states, as they tend to be poorer, and refugees and displaced people are economically more vulnerable even within those low-income states, so they have suffered more economically from vaccine inequity.

Liability

Several governments agreed to shield pharmaceutical companies like Pfizer and Moderna from negligence claims related to COVID‑19 vaccines (and treatments), as in previous pandemics, when governments also took on liability for such claims.

In the US, these liability shields took effect on 4 February 2020, when the US Secretary of Health and Human Services Alex Azar published a notice of declaration under the Public Readiness and Emergency Preparedness Act (PREP Act) for medical countermeasures against COVID‑19, covering "any vaccine, used to treat, diagnose, cure, prevent, or mitigate COVID‑19, or the transmission of SARS-CoV-2 or a virus mutating therefrom". The declaration precludes "liability claims alleging negligence by a manufacturer in creating a vaccine, or negligence by a health care provider in prescribing the wrong dose, absent willful misconduct." In other words, absent "willful misconduct", these companies can not be sued for money damages for any injuries that occur between 2020 and 2024 from the administration of vaccines and treatments related to COVID‑19. The declaration is effective in the United States through 1 October 2024.

In December 2020, the UK government granted Pfizer legal indemnity for its COVID‑19 vaccine.

In the European Union, the COVID‑19 vaccines were granted a conditional marketing authorization which does not exempt manufacturers from civil and administrative liability claims. The EU conditional marketing authorizations were changed to standard authorizations in September 2022. While the purchasing contracts with vaccine manufacturers remain secret, they do not contain liability exemptions even for side-effects not known at the time of licensure.

The Bureau of Investigative Journalism, a nonprofit news organization, reported in an investigation that unnamed officials in some countries, such as Argentina and Brazil, said that Pfizer demanded guarantees against costs of legal cases due to adverse effects in the form of liability waivers and sovereign assets such as federal bank reserves, embassy buildings or military bases, going beyond the expected from other countries such as the US. During the pandemic parliamentary inquiry in Brazil, Pfizer's representative said that its terms for Brazil are the same as for all other countries with which it has signed deals.

On 13 December 2022, the governor of Florida, Ron DeSantis, said that he will petition the state supreme court to convene a grand jury to investigate possible violations in respect to COVID-19 vaccines, and declared that his government would be able to get "the data whether they [the companies] want to give it or not".

Controversy

In June 2021, a report revealed that the UB-612 vaccine, developed by the US-based COVAXX, was a for-profit venture initiated by the Blackwater founder Erik Prince. In a series of text messages to Paul Behrends, the close associate recruited for the COVAXX project, Prince described the profit-making possibilities in selling the COVID‑19 vaccines. COVAXX provided no data from the clinical trials on safety or efficacy it conducted in Taiwan. The responsibility of creating distribution networks was assigned to an Abu Dhabi-based entity, which was mentioned as "Windward Capital" on the COVAXX letterhead but was actually Windward Holdings. The firm's sole shareholder, which handled "professional, scientific and technical activities", was Erik Prince. In March 2021, COVAXX raised $1.35 billion in a private placement.

Misinformation and hesitancy

This section is an excerpt from COVID-19 vaccine misinformation and hesitancy.[edit]

A protest against COVID-19 vaccination in London, United Kingdom

Anti-vaccination activists and other people in many countries have spread a variety of unfounded conspiracy theories and other misinformation about COVID-19 vaccines based on misunderstood or misrepresented science, religion, and law. These have included exaggerated claims about side effects, misrepresentations about how the immune system works and when and how COVID-19 vaccines are made, a story about COVID-19 being spread by 5G, and other false or distorted information. This misinformation has proliferated and may have made many people averse to vaccination. This has led to governments and private organizations around the world introducing measures to incentivize/coerce vaccination, such as lotteries, mandates and free entry to events, which has in turn led to further misinformation about the legality and effect of these measures themselves.

See also

• 2009 swine flu pandemic vaccine
• COVID‑19 drug development
• COVID‑19 drug repurposing research
• COVID‑19 vaccine card
• List of COVID‑19 vaccine authorizations
• Vaccine passports during the COVID‑19 pandemic

Further reading

Vaccine protocols

• "Protocol mRNA-1273-P301" (PDF). Moderna. Archived from the original (PDF) on 28 September 2020. Retrieved 21 September 2020.
• "Protocol C4591001 PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)" (PDF). Pfizer.
• "Protocol AZD1222 – D8110C00001" (PDF). AstraZeneca.
• "Protocol VAC31518COV3001; Phase 3 (Ensemble)" (PDF). Janssen Vaccines & Prevention.
• "Protocol VAC31518COV3009; Phase 3 (Ensemble 2)" (PDF). Janssen Vaccines & Prevention.
• "Protocol VAT00008 – Study of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older Protocol" (PDF). Sanofi Pasteur. Archived from the original (PDF) on 23 July 2021. Retrieved 30 July 2021.
• "Protocol 2019nCoV-301". Novavax.

External links

Wikiquote has quotations related to COVID-19 vaccine.

Wikinews has related news:

• New study analyzes the varying levels of protection offered by COVID-19 vaccines

• "COVID-19 vaccine tracker and landscape". World Health Organization (WHO).
• COVID‑19 Vaccine Tracker. Regulatory Affairs Professionals Society (RAPS)
• M.I.T. Lecture 10: Kizzmekia Corbett, Vaccines on YouTube
• M.I.T. Lecture 12: Dan Barouch, Covid-19 Vaccine Development on YouTube
• "COVID-19 vaccines: research and development". European Medicines Agency (EMA). 11 January 2021.
• "The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works". Johnson & Johnson. September 2020.
• "Coronavirus vaccine – weekly summary of Yellow Card reporting". UK Medicines and Healthcare products Regulatory Agency (MHRA).